Table 2 Clinical drug trial with documentation on ILC available
From: Reporting on invasive lobular breast cancer in clinical trials: a systematic review
SETTING | TRIAL | DRUG | PATIENT POPULATION | % ILC INCLUDED | SUB-ANALYSIS | CENTRAL PATHOLOGY |
|---|---|---|---|---|---|---|
Neoadjuvant | SAFIA59 | palbociclib (CDK4/6i) | HR+HER2− | 12.0 | No | No |
IMpassion03133,a | atezolizumab (ICI) | TNBC | 2.0 | No | No | |
GeparQuinto Lapatinib36 | lapatinib (TKI) | HR− HER2+ or HR+HER2+ if cN+ | 2.8 | Yes | No | |
EPHOS B60 | lapatinib (TKI) | HER2+ | 4.0 | No | No | |
GeparQuinto Everolimus35 | everolimus (mTORi) | HR− HER2+ or HR+HER2+ if cN+ | 10.8 | Yes | No | |
Adjuvant | MAINtenance Afinitor61 | everolimus (mTORi) | HR+HER2− | 16.3 | No | No |
Metastatic | PALOMA 223,b] | palbociclib (CDK4/6i) | HR+HER2− | 14.7 | No | No |
PALOMA 424,b] | palbociclib (CDK4/6i) | HR+HER2− | 3.8 | No | No | |
NCT0028165834,a] | lapatinib (TKI) | HER2+ | 4.7 | No | No | |
DETECT III62 | lapatinib (TKI) | HER2− with HER2+ CTCs | 9.8 | No | No | |
BELLE-238 | buparlisib (PI3Ki) | HR+HER2− | 13.0 | No | No | |
INPRES63 | everolimus (mTORi) | HR+HER2− | 26.0 | Yes | No | |
IMPROVE37 | everolimus (mTORi) | HR+HER2− | 24.7 | No | No |
